CD28-ARS2 Axis Drives PKM2 Splicing for CD8+ T Cell Metabolic Flexibility

Study Background and Research Question

Metabolic reprogramming is a hallmark of effective CD8+ T cell-mediated antitumor immunity. Upon activation, T cells must adapt to fluctuating nutrient and signaling microenvironments within tumors, necessitating metabolic flexibility to maintain effector functions. While the upregulation of glycolysis and glucose transporters through TCR and CD28-PI3K signaling is well established, the precise molecular mechanisms that allow CD8+ T cells to fine-tune glucose catabolism and sustain functional responses remained unclear. Specifically, the regulation of alternative splicing events in key glycolytic enzymes, such as pyruvate kinase M (PKM), and their impact on T cell metabolism and antitumor activity were previously uncharacterized.

Key Innovation from the Reference Study

Holling et al. (2024) uncover a novel signaling axis wherein CD28 costimulation induces the nuclear cap-binding complex adaptor protein ARS2 in mature CD8+ T cells. This upregulation of ARS2 enhances recruitment of splicing factors to pre-mRNAs, orchestrating a wide-ranging alternative splicing program upon T cell activation. Critically, the CD28-ARS2 axis directs splicing of PKM pre-mRNA to suppress PKM1 and favor the PKM2 isoform, which is associated with increased glycolytic flexibility, effector cytokine production, and improved antitumor responses. Notably, this regulatory mechanism is independent of PI3K signaling, revealing an unappreciated layer of immunometabolic control.

Methods and Experimental Design Insights

The researchers employed a combination of genetic, biochemical, and functional approaches to dissect the CD28-ARS2-PKM axis in murine and human CD8+ T cells. Key methodological highlights include:

• Genetic Models: CD8+ T cells with conditional deletion of ARS2 were generated to probe its specific role in alternative splicing and metabolism.
• Splicing Analysis: RNA sequencing and splicing-sensitive assays quantified alternative splicing events, with a focus on PKM exon inclusion/exclusion.
• Pathway Dissection: The contributions of PI3K and other canonical pathways were tested via pharmacological inhibition and genetic approaches, establishing the independence of the ARS2-mediated splicing program from PI3K signaling.
• Functional Readouts: Metabolic flux assays, cytokine profiling (e.g., IFNγ production), and in vivo tumor models assessed the impact of ARS2 and PKM isoform usage on CD8+ T cell functionality and antitumor efficacy.

Core Findings and Why They Matter

Several critical findings emerge from this work:

1. ARS2 as a Splicing Regulator: CD28 signaling robustly increases ARS2 levels post-activation, and ARS2 is directly required for approximately one-third of activation-induced alternative splicing events, including PKM.
2. PKM Isoform Switch: The ARS2-driven splicing program suppresses PKM1 and promotes PKM2 expression in CD8+ T cells, a switch previously associated mainly with oncogenic and proliferative states.
3. Metabolic Flexibility and Effector Function: PKM2-expressing CD8+ T cells display enhanced glycolytic reprogramming, sustain higher cytokine output (notably IFNγ), and improve tumor control in vivo. This underscores the importance of alternative splicing in immunometabolism.
4. PI3K-Independent Mechanism: The alternative splicing of PKM is uncoupled from classical PI3K signaling, highlighting a distinct posttranscriptional regulatory layer that could be targeted for therapeutic intervention.

Together, these findings reposition alternative splicing—specifically the CD28-ARS2-PKM2 pathway—as a central determinant of T cell metabolic fitness and functional plasticity within the tumor microenvironment. By elucidating this mechanism, the study paves the way for strategies to enhance T cell-based immunotherapies through modulation of splicing programs, potentially overcoming metabolic barriers that limit antitumor immunity.

Comparison with Existing Internal Articles

Several recent thought-leadership articles have explored the broader context of immunometabolism and metabolic adaptation in cancer and neuroinflammation research. For instance, "Probenecid at the Nexus of Multidrug Resistance, Immunometabolism, and Neuroinflammation" integrates transporter biology and the emerging role of metabolic flexibility in CD8+ T cells, referencing the importance of pathways such as the PKM splicing program. It frames small molecule inhibitors like Probenecid (4-(dipropylsulfamoyl)benzoic acid) as valuable research tools for dissecting multidrug resistance and immunometabolic crosstalk. Similarly, "Probenecid at the Nexus of Multidrug Resistance and Immunometabolism" discusses practical strategies for leveraging transporter inhibitors to probe and potentially modulate immune cell metabolism in both oncology and neurobiology. These internal resources complement the present study by emphasizing the translational potential of targeting metabolic and splicing pathways in immune cells.

Limitations and Transferability

While the study leverages robust genetic and functional assays, several limitations should be considered. Most data derive from murine models and in vitro human T cell systems; thus, clinical relevance in human immunotherapy settings remains to be fully established. The focus on CD8+ T cells, while mechanistically clear, may not capture the complexity of metabolic regulation across other immune subsets or within diverse tumor microenvironments. Additionally, the study does not address possible feedback mechanisms or compensatory pathways that may modulate PKM2 reliance in chronic or exhausted T cell states. Further research is needed to determine how these findings translate to patient settings and whether pharmacological manipulation of the ARS2-PKM2 axis is feasible and safe.

Protocol Parameters

• CD8+ T cell activation: Stimulate purified CD8+ T cells with anti-CD3/CD28 antibodies (1-2 μg/mL) for 24-48 hours to induce ARS2 expression and alternative splicing programs.
• Splicing analysis: Collect RNA at 24-48 hours post-activation for RT-PCR or RNA-seq targeting PKM exon 9/10 inclusion.
• PI3K pathway controls: Include PI3K inhibitor (e.g., LY294002, 10 μM) in parallel cultures to confirm PI3K-independent splicing effects.
• Functional assays: Assess IFNγ production by intracellular cytokine staining or ELISA at 48-72 hours post-activation.
• In vivo tumor models: For translational studies, adoptively transfer activated CD8+ T cells into tumor-bearing mice and monitor tumor growth, cytokine production, and persistence.

Why this cross-domain matters, maturity, and limitations

The intersection of immunometabolic reprogramming and multidrug resistance research has practical implications for both oncology and neurobiology. Molecules that modulate metabolic flexibility or transporter function, such as Probenecid, have been explored for their ability to reverse drug resistance in leukemia and confer neuroprotection in cerebral ischemia/reperfusion injury, partly through inhibition of astrocyte and microglia proliferation. However, direct modulation of alternative splicing in immune cells remains at an early research stage, with most mechanistic insights derived from preclinical models. Further work is required to move from bench to bedside.

Research Support Resources

Researchers interested in probing transporter function, multidrug resistance reversal in leukemia, or neuroprotection in cerebral ischemia/reperfusion injury may consider using Probenecid (SKU B2014), an established inhibitor of organic anion transporters and MRPs. Probenecid's ability to modulate efflux pathways and influence immune and glial cell signaling has been highlighted in recent mechanistic reviews. While not directly acting on alternative splicing, Probenecid provides a valuable tool for investigating metabolic and transporter crosstalk in experimental workflows that build on the immunometabolic findings described above. For storage and handling recommendations, consult the product information. Always refer to up-to-date safety and usage guidelines and tailor protocols to your experimental system.